Myriad Genetics (MYGN) and PATHOMIQ entered into a strategic collaboration for Myriad to exclusively license PATHOMIQ_PRAD, PATHOMIQ’s AI technology platform for prostate cancer, in the United States.

Key market opportunities include advancements in gene and cell therapies, the integration of AI in pharmaceutical R&D, partnerships between major drug firms and smaller biotech companies, and emerging ...

LIMA, Peru, Dec. 1, 2024 /PRNewswire/ -- MGI Tech Co., Ltd. ("MGI"), a company committed to building core tools and technologies that drive innovation in life science, announced a partnership with the ...

The implementation of MGI Tech's next-generation genomic sequencing (NGS) technologies will strengthen scientific research in the country, enabling the identification of key genetic variations, ...

The Jackson Laboratory, Bar Harbor, Maine’s genetics research company, is setting up a research presence in Sarasota, Fla., that will focus on treatments for heart disease, Alzheimer’s ...

New technological advancements have allowed scientists to look at the entire human genome. But what are genomics, and why is it relevant? Gabbard fires leaders of intelligence group that wrote ...

Researchers used evolutionary genetics and CRISPR gene editing tech to develop an innovative treatment for gout. The approach has yet to be tested in humans.